A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma
NCT03016091
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
18
Enrollment
OTHER
Sponsor class
Stopped
Slow accrural, dismal results
Conditions
Atypical Meningioma
Anaplastic Meningioma
Hemangiopericytoma
Interventions
DRUG:
Pembrolizumab
Sponsor
Rabin Medical Center